Innate Pharma (IPHA) Research & Development (2019 - 2025)

Innate Pharma (IPHA) has reported Research & Development for 7 consecutive years, with -$49.6 million the latest figure, recorded in Q4 2025.

• Quarterly Research & Development rose 16.08% year-over-year to -$49.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$165.2 million (up 13.85% YoY) and the FY2025 annual result came in at $49.6 million, down 16.08% from the prior year.
• Research & Development declined to -$49.6 million in Q4 2025 per IPHA's latest filing, from -$23.4 million in the prior quarter.
• Over the last five years, Research & Development for IPHA reached as high as -$23.4 million in Q2 2025 and fell as low as -$63.8 million in Q4 2023.
• A 5-year average of -$43.0 million and a median of -$42.7 million in 2025 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2021 — Research & Development surged 30.81% — and 2023, when it dropped 26.03%.
• Year by year, Research & Development stood at -$53.5 million in 2021, then decreased by 9.91% to -$58.8 million in 2022, then dropped by 8.44% to -$63.8 million in 2023, then advanced by 7.22% to -$59.2 million in 2024, then gained by 16.08% to -$49.6 million in 2025.
• According to Business Quant data, Research & Development over the past three periods registered -$49.6 million, -$23.4 million, and -$59.2 million for Q4 2025, Q2 2025, and Q4 2024 respectively.